Clinical Utility and Reimbursement of Next-Generation Sequencing-Based Testing for Myeloid Malignancies

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Next-generation sequencing (NGS) is crucial for myeloid malignancy diagnosis, risk stratification, and management.
• Clinical practice guidelines increasingly incorporate NGS, with genetic alterations defining disease classification.
• Reimbursement for these vital diagnostic tests remains uncertain.

Purpose of the Study:

• To analyze the clinical impact, ordering patterns, prior authorization, and reimbursement outcomes of NGS panels for myeloid malignancies.
• To assess the utility of a 50-gene myeloid NGS panel and a 15-gene myeloproliferative neoplasm subpanel.
• To identify discrepancies between clinical utility and payor reimbursement policies.

Main Methods:

• Retrospective analysis of 505 samples from 477 patients undergoing myeloid NGS.
• Evaluation of test results for clinical utility, including diagnostic, prognostic, and therapeutic implications.
• Review of prior authorization success rates and reimbursement outcomes from commercial and government payors.

Main Results:

• 98% of NGS tests yielded clinically useful data, informing diagnosis (89%), prognosis (94%), and potential therapies (19%).
• NGS aided in risk stratification, monitoring disease progression, and defining diagnoses.
• Prior authorization was approved for only 45% of requests, and 51% of cases were reimbursed, often denied for lack of medical necessity.

Conclusions:

• NGS provides substantial clinical utility in myeloid malignancy management.
• A significant gap exists between the clinical value of NGS tests and current payor reimbursement policies.
• Addressing reimbursement barriers is essential for widespread adoption of NGS in clinical practice.